Abstract: A robotic surgical system and method of selectively binding articulation limits to a surgical instrument includes detecting a proximal or a distal linear movement of the surgical instrument, calculating a distance between a tool center point of the surgical instrument after the proximal or the distal linear movement and a remote center of motion, assigning and binding an articulation limit to the surgical instrument based on the calculated distance when the detected linear movement is distal linear movement, and assigning a non-binding articulation limit to the surgical instrument based on the calculated distance when the detected linear movement is proximal a linear movement.

Abstract: A method for identifying urological health information. The method includes storing user-defined inputs provided by a user, monitoring a fluid volume of urine processed by the user, storing parameters regarding the fluid volume of urine, utilizing a machine learning algorithm to provide processed data based on the user-defined inputs and stored parameters, and providing feedback based on the processed data.

Abstract: Systems and methods to generate synthetic images for use in a machine learning training set. The process begins with accessing a database of real-world 3-D images of equipment in a power grid, the 3-D images of equipment include 3-D measurements to create a dimensionally accurate and photorealistic model of the equipment. Optionally, the 3-D images could be aged or weathered using imaging editing software. Next, a database of real-world photographs of scenes in which the equipment is installed is accessed. Optionally, the identical scenes can be captured at different times of day, different times of the year, and at different perspectives. Next, using image editing software, the 3-D images of equipment is inserted into at least one of the scenes to form a synthetic image based on a combination of the equipment and the scene in which each of the equipment and the scene were previously captured independently of each other.

Abstract: Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise a RAF inhibitor. Some embodiments comprise combination therapy featuring the RAF inhibitor with at least one oncology therapeutic agent.

Abstract: The present disclosure provides devices for removal of hair, such as by cutting of the hair. The devices can include a cutting assembly or blade assembly that can include at least one moving blade and at least one stationary blade. The blades may be provided within a blade assembly housing. A stationary blade can include an externally facing edge with a curved arrangement that improves passage of the blade assembly across skin for hair removal with reduced chance for nicking of skin or other discomfort. The blade assembly may be combined with a handle. The blade assembly may be attached to the handle so that the blade assembly is arrange for continuous rotation to a desired angle to improve case of use thereof.

Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Abstract: Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise a RAF inhibitor. Some embodiments comprise combination therapy featuring the RAF inhibitor with at least one oncology therapeutic agent.

Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise a RAF inhibitor. Some embodiments comprise combination therapy featuring the RAF inhibitor with at least one oncology therapeutic agent.

Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are compositions and methods for the treatment of a triple-negative breast cancer, ovarian cancer and castration-resistant prostate cancer. Said compositions comprise CDK12/13 inhibitors.

Abstract: Provided herein are compounds which are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.